Neurocrine Biosciences (NBIX) Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms
Tweet Send to a Friend
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that new long-term data from the KINECT 4 Phase III open-label study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
